PROTEOMIC PROFILING OF GLOMERULI FROM KIDNEYS WITH HYPERTENSIVE NEPHROPATHY REVEALS SIGNATURE OF DISEASE PROGRESSION
NEPHROLOGY DIALYSIS TRANSPLANTATION(2021)
摘要
Abstract Background and Aims Hypertensive nephropathy (HN) often represents an unspecific clinical diagnosis applied to non-diabetic, chronic kidney disease (CKD) patients with low-level proteinuria and elevated blood pressure. Kidney biopsy-based findings are the diagnostic gold standard, but they are not entirely specific and there is a need for prognostic markers. We aimed at defining candidate markers that predict disease progression based on protein signatures. Method We included adult patients (n=17) with an eGFR >30 ml/min/1.73m2 and proteinuria <3g/d from the Norwegian Kidney Biopsy Registry (NKBR). Subjects were divided into two groups: stable patients (n=9) and subjects with HN progression (n=8) leading to end-stage renal disease (ESRD) within 20 years of follow-up. Glomerular cross-sections were microdissected from 10 μm whole archival kidney biopsy sections and processed for protein extraction. Proteomic analyses were performed at our local facility PROBE in Bergen using a Q-exactive HF mass spectrometer. Abundances of glomerular proteins were compared between the two groups. Results Amongst a total of 1870 quality filtered proteins, we identified 58 proteins with absolute fold change (FC) ≥1.5, p≤0.05, including 17 proteins with absolute FC ≥2, indicative of HN progression (highest FC: Cadherin 16 and UDP-glucuronosyl-transferase 2B7). Hierarchical cluster and principal component analysis (PCA) with the 17 proteins showed clear separation of samples into these two disease clusters of HN progressors and non-progressors. To find proteins as biomarkers for the identification of progressors, we employed unsupervised K nearest neighbors validation algorithm coupled with leave-one-out internal cross-validation. Thereby, a set of five proteins (incl. cadherin 16) performed best and separated the two groups in a PCA, as shown in Figure 1. This classifier classified 16 of 17 samples correctly (AUC 0.993), misclassifying only one progressor sample. Applying Geneset Enrichment Analysis (GSEA; The Broad Institute, USA), in general metabolic pathways were up-regulated in progressors and structural cell pathways up-regulated in non-progressors. Ingenuity Pathway Analysis (IPA; Qiagen, USA) identified Epithelial Adherens Junction Signaling as the most affected canonical pathway (p=1.95E-06); five of six member proteins were down-regulated in progressors. Conclusion Glomerular proteomic profiling can be used to distinct progressors from non-progressors in HN.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要